News Center

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

>Toripalimab has become the first and only approved immuno-oncology treatment for NPC in Singapore

君实生物宣布特瑞普利单抗在新加坡获批

>特瑞普利单抗是新加坡首个且唯一获批用于鼻咽癌的肿瘤免疫治疗药物

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC

Junshi Biosciences Announces Ongericimab’s NDA Approval in China

>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)